The OX-39 antibody reacts with the α chain of the IL-2 receptor on T lymphoblasts and thymic and splenic dendritic cells. CD25 has also been detected on rat intestinal epithelial cells. It has been reported that OX-39 mAb weakly blocks binding of IL-2 to T-cell blasts and that it blocks IL-2 stimulated epithelial cell migration in an in vitro model of wound healing. Use of this product can fall under one or more claims of the following patents licensed to Becton, Dickinson and Company: US Patent Nos. 5,445,939, 5,656,446, 5,843,689, European Patent No. 319,543, Canadian Patent No. 1,296,622, Australian Patent No. 615,880, and Japanese Patent No. 2,769,156. This antibody is routinely tested by flow cytometric analysis. Other applications were tested during antibody development only or reported in the literature.
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Stock
4 °C
Stockage commentaire
Store undiluted at 4°C.
Josien, Heslan, Soulillou, Cuturi: "Rat spleen dendritic cells express natural killer cell receptor protein 1 (NKR-P1) and have cytotoxic activity to select targets via a Ca2+-dependent mechanism." dans: The Journal of experimental medicine, Vol. 186, Issue 3, pp. 467-72, (1997) (PubMed).
Dignass, Podolsky: "Interleukin 2 modulates intestinal epithelial cell function in vitro." dans: Experimental cell research, Vol. 225, Issue 2, pp. 422-9, (1996) (PubMed).
Paterson, Jefferies, Green, Brandon, Corthesy, Puklavec, Williams: "Antigens of activated rat T lymphocytes including a molecule of 50,000 Mr detected only on CD4 positive T blasts." dans: Molecular immunology, Vol. 24, Issue 12, pp. 1281-90, (1988) (PubMed).
Tellides, Dallman, Kupiec-Weglinski, Diamantstein, Morris: "Functional blocking of the interleukin-2 receptor (IL-2R) may be important in the efficacy of IL-2R antibody therapy." dans: Transplantation proceedings, Vol. 19, Issue 5, pp. 4231-3, (1987) (PubMed).